Etoposide (Page 4 of 4)
REFERENCES
- 1.
- Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, US Government Printing Office, Washington, DC 20402.
- 2.
- AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. JAMA 1985 March 15.
- 3.
- National Study Commission on Cytotoxic Exposure — Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
- 4.
- Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia 1:426-428, 1983.
- 5.
- Jones RB, et al. Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center. CA — A Cancer Journal for Clinicians (Sept/Oct):258–263, 1983.
- 6.
- American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm 47:1033–1049, 1990.
- 7.
- Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines). Am J Health-Syst Pharm 53:1669–1685, 1996.
Manufactured By:
Intas Pharmaceuticals Limited,
Plot No.: 457, 458, Village – Matoda, Bavla Road,
Ta.- Sanand, Dist.-Ahmedabad – 382 210, India.
For BluePoint Laboratories
Issued November, 2014
Package/Label Display Panel
Etoposide Injection USP, 5 mL Multiple Dose Vial – Vial Label
100 mg/5 mL (20 mg/mL), NDC 68001-265-22
Package/Label Display Panel
Etoposide Injection USP, 5 mL Multiple Dose Vial – Carton Label
100 mg/5 mL (20 mg/mL), NDC 68001-265-25
ETOPOSIDE etoposide injection | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
|
Labeler — BluePoint Laboratories (985523874) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Intas Pharmaceuticals Ltd | 725927649 | MANUFACTURE (68001-265), ANALYSIS (68001-265) |
Revised: 06/2018 BluePoint Laboratories
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.